drugset
drugset / Trial / NCT01273376

Safety and Efficacy of RX-10100 to Treat Major Depressive Disorder

NCT01273376 ↗

Phase 2 Completed 314 enrolled Rexahn Pharmaceuticals, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether RX-10100 are effective in the treatment of Major Depressive Disorder (MDD).

Timeline

Start
2010-12
Primary completion
2011-09
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject clavulanic acid Small molecule — Oral

Indications

major depressive disorder